Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03448978 · ClinicalTrials.gov registry record · Phase 1
Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
A Phase 1 study, sponsored by Cartesian Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT03448978: Clinical Trial Phase 1 study, sponsored by Cartesian Therapeutics.
NCT03448978 is a Phase 1 study that was terminated before completion, run by Cartesian Therapeutics. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03448978, a Phase 1 study, was terminated before completion, sponsored by Cartesian Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-08 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
Primary Outcome
Incidence (number) of Treatment-Emergent Adverse Events \[Safety and Tolerability\]. Descriptive statistics by incidence rate, body system classification, severity, and causality \[per protocol definitions\]
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL Descartes-08
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2018-03-08 |
| Est. Completion | 2021-06-03 |
| Phase | Phase 1 |
Why NCT03448978 stopped before completion
NCT03448978 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT03448978 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03448978 about?
NCT03448978 is a clinical study titled "Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma". This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-08 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
What is the current status of trial NCT03448978?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2018-03-08. Estimated completion is 2021-06-03.
What interventions are being tested in trial NCT03448978?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Descartes-08 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03448978?
This trial is sponsored by Cartesian Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03448978's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI